| May 12 |
Caribou extends gains as SVB Leerink raises target after early data for CAR-T asset
|
| May 12 |
Caribou's Lymphoma Candidate Shows 100% Response Rate In Early-Stage Study
|
| May 12 |
Caribou Biosciences rises 27% on early-stage CAR-T therapy data for non-Hodgkin lymphoma
|
| May 12 |
Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy
|
| May 12 |
Here's What Analysts Are Forecasting For Caribou Biosciences, Inc. (NASDAQ:CRBU) After Its First-Quarter Results
|
| May 11 |
Caribou Biosciences Announces Appointment of David Johnson to its Board of Directors
|
| May 9 |
Caribou Bioscience GAAP EPS of -$0.32 beats by $0.02, revenue of $2.66M misses by $0.54M
|
| May 3 |
Caribou Biosciences to Present at Upcoming Investor Conference
|
| May 2 |
Caribou Biosciences Announces Presentation of chRDNA Platform Data at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT)
|
| Apr 26 |
Caribou Biosciences: Selling Close To Cash Balance
|
